uBriGene uVivo™ LVV Platform at ASGCT 2026
May 11, 2026
uBriGene Biosciences will take center stage at the ASGCT 2026 Annual Meeting (May 11–15, Boston), joining global leaders shaping the future of cell and gene therapy. As one of the field’s most influential events, ASGCT brings together innovators across academia and industry to define the next wave of genetic medicine - and increasingly, that future is in vivo.
At this year’s meeting, uBriGene will spotlight its uVivo™ LVV Platform, an IND-ready in vivo CAR-T technology powered by targeted Cocal-G lentiviral vector engineering - designed to overcome key limitations of traditional ex vivo approaches.
🔬 Poster Presentation
High-Yield In Vivo CAR-T Development Enabled by CD7 Nanobody and Detargeted Cocal-G Lentiviral Vectors
from 05:00PM on Thursday, May 14
uVivo™ LVV enables precise, targeted CAR delivery to T cells in vivo, supporting rapid CAR-T generation directly in patients. This single-dose approach represents a step-change toward scalable, off-the-shelf CAR-T therapies, reducing manufacturing complexity, timelines, and cost barriers that have historically limited patient access
As the industry transitions from personalized, labor-intensive models to programmable in vivo cell engineering, uBriGene is positioning itself at the forefront - combining advanced vector design with GMP-ready manufacturing to accelerate clinical translation.
Beyond platform innovation, uBriGene delivers integrated CDMO solutions spanning lentiviral vectors, AAV, and RNA technologies, enabling partners to move faster from concept to IND and beyond.
Meet uBriGene at Booth #1401
Connect with our experts to explore how uVivo™ LVV and our GMP platforms can power your next breakthrough.
Whether you are developing cell therapies, viral vectors, gene therapies, or RNA-based technologies, uBriGene provides integrated solutions spanning process development, GMP manufacturing, and scalable platform technologies.
Contact us the uBriGene team to schedule a meeting and explore how we can accelerate your advanced therapy program.